Gerresheimer (GXI) Q4 2025 earnings summary

Executive summary

• Extensive compliance and forensic investigations concluded, resulting in restated and audited 2025 financials with an unqualified audit opinion; all accounting and governance matters addressed.

• Management focus on governance, transformation, and capital structure improvement, including the sale of Centor and debt refinancing, with broad creditor support via stabilization agreement.

• New executive board and leadership changes implemented, driving governance and transformation initiatives.

• Gerresheimer Transformation Offensive (GTO/gto) launched, targeting operational and cash excellence across five workstreams.

Financial highlights

• 2025 revenue reached EUR 2.3 billion, up 17% mainly due to the Bormioli Pharma acquisition; organic/legacy business growth was flat at +0.3%.

• Adjusted EBITDA margin at 16.8%, within guidance but down from 19.4% in FY24; adjusted EBITDA at EUR 384m, down 1% year-over-year.

• Adjusted EPS for FY25 at EUR -1.65, reflecting significant impairments and restructuring.

• Free cash flow before M&A between EUR -50 million and EUR -100 million, mainly impacted by reduced factoring; actual FY25 free cash flow before M&A at EUR -86m.

• CapEx at EUR 295 million, with two-thirds allocated to growth projects.

Outlook and guidance

• 2026 revenue expected in the lower half of EUR 2.3–2.4 billion; adjusted EBITDA margin guided at 17–18%.

• Free cash flow for FY26 expected to be negative EUR -50 to -100m, mainly due to reduced factoring.

• Focus on cash generation and margin improvement, with GTO/gto expected to contribute EUR 10–20 million EBITDA in 2026 and midterm targets of 200–400bps profitability improvement.

• Acceleration of revenue growth and margin improvement anticipated in the second half of the year.